| Species |
Human |
| Protein Construction |
HLA-A*24:02&B2M&GP100 Intron 4 (VYFFLPDHL) Monomer[Gly25-Thr305(HLA-A*24:02), Ile21-Met119(B2M) and VYFFLPDHL peptide]
Accession # AAA59600.1(HLA-A*24:02)&P61769(B2M)&VYFFLPDHL |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
50.40 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 55-63 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Glycoprotein 100, gp100 or Melanocyte protein PMEL is 661 amino acids long and is a type I transmembrane glycoprotein enriched in melanosomes, which are the melanin-producing organelles in melanocytes. This protein is involved in melanosome maturation. The Human HLA-A*0201 gp100 (YLEPGPVTA) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and YLEPGPVTA peptide of the gp100. |
| Synonyms |
HLA-A*24:02; HLA-A2402; MHC I; gp100; Glycoprotein 100; ME20-M; P100; GP100 Intron 4; Intron 4 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
